Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

By Zacks Investment ResearchStock MarketsJan 31, 2021 10:38PM ET
www.investing.com/analysis/drugbiotech-stock-earnings-on-feb-2-amgn-pfe--ctlt-200557742
Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT
By Zacks Investment Research   |  Jan 31, 2021 10:38PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

A few large pharma companies have already reported their fourth-quarter results. Johnson & Johnson JNJ and Eli Lilly (NYSE:LLY) surpassed estimates for both earnings and sales in the fourth quarter of 2020, while Swiss pharma giant Novartis missed estimates for both.

Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.

Per the Earnings Trends report as of Jan 27, 10.9% of the companies in the Medical sector, constituting nearly 28.8% of the sector’s market capitalization, reported earnings. 83.3% of the companies managed to surpass estimates for both earnings and sales. Earnings decreased 7% year over year on 11% higher revenues. Overall, fourth-quarter earnings for the Medical sector are expected to rise 8.2% on 11.4% sales increase.

Let’s analyze the three drug/biotech companies that are set to report earnings results on Feb 2.

Pfizer Inc. (NYSE:PFE) PFE

The drug giant’s performance has been mixed with the company exceeding earnings expectations in three of the last four quarters, while missing the same in one. The company has delivered an earnings surprise of 8.48% in the past four quarters, on average.

Our proven model does not conclusively predict an earnings beat for Pfizer this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Pfizer has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for earnings stands at 45 cents per share.

Investors will be keen to know about sales of Pfizer’s key brands, Eliquis, Ibrance and Inlyta, and contributions from new drug Vyndaqel/Vyndamax in the fourth-quarter earnings call. Also, Pfizer and partner BioNTech successfully developed BNT162b2, a two-shot vaccine for COVID-19, which is now approved for emergency/temporary use in several countries. The vaccine sales are likely to have added to revenues in the fourth quarter.

Amgen Inc (NASDAQ:AMGN). AMGN

The large biotech’s performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 11.65%, on average.

Amgen has an Earnings ESP of +0.03% and a Zacks Rank #3, indicating a likely earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here.

Our previous article showed that Amgen did not have the favorable combination to beat on earnings in the soon-to-be-reported quarter. However, estimates have changed thereafter and we are more certain of a beat now.

The Zacks Consensus Estimate for earnings stands at $3.36 per share per share.

The recovery from the peak impact of the COVID-19 pandemic is expected to have continued in the fourth quarter of 2020. However, the resurgence in COVID-19 infection rates is likely to have acted as a headwind this time around.

Biosimilars may have once again been an important contributor to top-line growth of Amgen while increasing generic competition for its legacy products are likely to have hurt the top line.

Catalent (NYSE:CTLT), Inc. CTLT

The company exceeded earnings expectations in three of the last four quarters while meeting the same in one. Catalent has delivered an earnings surprise of 5.59% in the past four quarters, on average.

Catalent has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for earnings stands at 56 cents per share. The company will report earnings results for second quarter of fiscal year 2021 ended Dec 31, 2020.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Catalent, Inc. (CTLT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT
 

Related Articles

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email